{"id":6035,"date":"2023-12-18T10:00:56","date_gmt":"2023-12-18T01:00:56","guid":{"rendered":"https:\/\/hbio.jp\/news\/?p=6035"},"modified":"2024-04-04T18:48:30","modified_gmt":"2024-04-04T09:48:30","slug":"20241218","status":"publish","type":"post","link":"https:\/\/hbio.jp\/news\/en\/2023\/12\/18\/20241218\/","title":{"rendered":"Follow-up survey conducted Among HIGH-RISK N-NOSE Patients"},"content":{"rendered":"

HIROTSU Bio\nScience Inc. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu\n(Hereinafter referred to as \u201cHIROTSU\u201d), has conducted a follow-up survey\ntargeted at individuals who were notified of their test results between January\nand August 2023 using “N-NOSE” and were determined to be at high\nrisk. We are now publishing the first results report of this survey.<\/strong><\/p>\n\n\n\n

Our company conducted this survey to\nfurther facilitate understanding of “N-NOSE” and to ensure that\neveryone can use it with peace of mind. The survey targeted individuals who\nused “N-NOSE” between January and August 2023, were notified of their\nresults, and received a high-risk determination. We surveyed 228 individuals\nwho, after receiving their “N-NOSE” results, visited a hospital for\nfurther testing, asking whether cancer was actually found. The survey was\nconducted with the consent of the participants.<\/p>\n\n\n\n

Survey Report:<\/strong>
\u30fbOut of 228 respondents who went to a hospital for testing following a high-risk determination by “N-NOSE”, 47 were diagnosed with cancer.
\u30fbOver 65% of those diagnosed with cancer were discovered at stage 0 or 1.
\u30fbAbout 50% of those diagnosed with cancer were found to have abnormalities through endoscopy or MRI.<\/p>\n\n\n\n

In this survey, out of 228\nindividuals who received a high-risk determination from “N-NOSE” and\nwent to a hospital for cancer testing, 47 (20.6%) were actually found to have\ncancer. While this survey is not a clinical study and thus the results are not\nintended to explain the accuracy of “N-NOSE”, the positive hit rate\nof general cancer screenings (the probability of finding cancer after being\nreferred for a detailed examination) is reported to be about 1~5%*1<\/sup>\nfor comparison. Additionally, as mentioned in the testimonials, it was found\nthat the high-risk determination from “N-NOSE”, even without any\nsymptoms, led to behavioral changes that resulted in early cancer detection\nupon receiving further examination at a hospital. Furthermore, it was\ndiscovered that most of the cancers were identified by tests such as endoscopy\nand MRI, which are generally regarded as capable of early detection, indicated\nby findings.<\/p>\n\n\n\n

*1 Calculated based on “Cancer\nRegistration & Statistics” from the National Cancer Center Cancer\nInformation Service (detection and positive hit rate).<\/p>\n\n\n\n

For more detailed survey results,\nplease refer to the “Survey Summary” below. Our company will continue\nto strive to provide information so that everyone can use our services with\nconfidence.<\/p>\n\n\n\n

Survey target: <\/strong>
\u30fbThose who used N-NOSE and were notified of their test results between January and August 2023 and were judged to be at high risk. <\/p>\n\n\n\n

Number of respondents: <\/strong>
228 items <\/p>\n\n\n\n

Investigation method: <\/strong>
Internet survey, telephone survey, interviews <\/p>\n\n\n\n

Survey items: <\/strong>
1.Cancer locations diagnosed
2.Cancer stage at diagnosis
3.Tests taken after taking the N-NOSE test (multiple answers allowed) 4.Test type responsible for successful cancer diagnosis
5.Testimonials from users<\/p>\n\n\n\n

\u25a0Survey results<\/strong>
1. Cancer locations diagnosed<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Following a high-risk determination\nfrom N-NOSE, the most common site diagnosed with cancer after hospital testing\nwas the colon.<\/p>\n\n\n\n

2.Cancer stage at diagnosis<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

More than 65% of the individuals who received a confirmed diagnosis of cancer after undergoing testing in a hospital following a high-risk determination from N-NOSE were found to be at stage 0 or 1.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

When focusing on the five major\ncancers, approximately 70% were discovered at stage 0 or 1. Compared to the\nproportions of each stage at the time of confirmed cancer diagnosis for the\nfive major cancers reported by the Ministry of Health, Labour and Welfare*2, it\nwas found that individuals with a high-risk determination from N-NOSE had a\nhigher percentage of early detection, especially at stage 0.<\/p>\n\n\n\n

*2 \u539a\u751f\u52b4\u50cd\u7701\u5065\u5eb7\u5c40\u304c\u3093\u30fb\u75be\u75c5\u5bfe\u7b56\u8ab2\u300c\u5168\u56fd\u304c\u3093\u767b\u9332 \u7f79\u60a3\u6570\u30fb\u7387 \u5831\u544a2019\u300d<\/a><\/p>\n\n\n\n

Next, when focusing on colon cancer, which had the highest number of reports, the results showed a higher number of detections at stage 0 or 1, especially at stage 0, compared to the report from the Cancer and Disease Control Division of the Health Bureau, Ministry of Health, Labour and Welfare.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

3.Tests taken after taking the N-NOSE test (multiple answers allowed) <\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Regarding the tests that users\nunderwent at hospitals after receiving a high-risk determination from N-NOSE,\nthere was a high occurrence of MRI, endoscopy, and CT scans.<\/p>\n\n\n\n

4.Test type responsible for successful cancer diagnosis<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

It was found that nearly 50% of individuals were determined to have findings through endoscopy or MRI after undergoing the N-NOSE examination. Endoscopy, which is said to enable early detection, had the highest frequency among these tests.<\/p>\n\n\n\n

Download PDF<\/a><\/a><\/div>","protected":false},"excerpt":{"rendered":"

HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative; Takaaki Hirotsu (Hereinafter referre […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_locale":"en_US","_original_post":"6035","footnotes":""},"categories":[3],"tags":[],"class_list":["post-6035","post","type-post","status-publish","format-standard","hentry","category-press-release","en-US"],"acf":[],"_links":{"self":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/6035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/comments?post=6035"}],"version-history":[{"count":5,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/6035\/revisions"}],"predecessor-version":[{"id":6048,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/posts\/6035\/revisions\/6048"}],"wp:attachment":[{"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/media?parent=6035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/categories?post=6035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hbio.jp\/news\/en\/wp-json\/wp\/v2\/tags?post=6035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}